Hemophagocytic Lymphohistiocytosis clinical trials
11 active trials name this condition. Describe your situation to see which ones look like a fit.
By location
- Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)
- Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome
- Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
- Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
- Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
- Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis
- INTO-HLH: A Disease Registry for Patients With Hemophagocytic Lymphohistiocytosis (HLH)
- Histiocytic Disorder Follow-up Study
- Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
- Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
- Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Hemophagocytic Lymphohistiocytosis” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.